Additional classification is based on loss of nuclear ATRX chromatin remodeler (ATRX), telomerase reverse transcriptase (TERT) expression and mutations within its promoter, and several DNA methylation subgroups (G-CIMP, Glioma CpG island methylator phenotype) (23, 26–28). The gene discussed is ATRX; the disease is central nervous system cancer.